HEM:TSXV, Hemostemix Inc.

HEM stock overview

Hemostemix Inc. (HEM:TSXV) closed at $0.060 on October 16, 2026, unchanged on the day. The stock trades 45.5% below its 52-week high of $0.110 and 50.0% above its 52-week low of $0.040. Over the past year, it lost 40.0%. Hemostemix Inc. is part of the Life Sciences sector (Biotechnology).

Key figures

Price: $0.060
Day change: 0.00%
Volume: 15,000
Average volume: 26,800
Market cap: 12M+
52-week range: $0.040 – $0.110
50-day average: $0.069
200-day average: $0.070

Performance

5D	1M	3M	1Y
0.00%	-20.00%	-7.69%	-40.00%

Price action over the past year

In 252 trading sessions since October 16, 2025, HEM closed higher on 55 days (22%). Its best day was July 8, 2026 (+33.33%) and its worst was October 13, 2026 (-20.00%). The stock moved 10% or more in a single session 20 times. It opened at least 5% above the previous day's high 24 times.

Recent signals

Oct 16, 2026: Down 40.0% over 365 days, from $0.100 (Dips & Crashes scanner)
Sep 23, 2026: News catalyst: Private Placement (News Catalysts scanner)

HEM news

Oct 7, 2026: Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
Sep 28, 2026: Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
Sep 23, 2026: Hemostemix Non Brokered Private Placement
Aug 20, 2026: Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
Aug 12, 2026: Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
Jul 30, 2026: Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
Jul 28, 2026: Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
Jul 22, 2026: Hemostemix Grants Stock Options

About Hemostemix Inc.

Hemostemix Inc is a biotechnology company. The Company is engaged in developing, manufacturing and commercializing adult stem cell therapies to treat a variety of diseases.

Similar stocks

Find more stocks like HEM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.